ECHO - Esketamine CoHOrt study 54135419TRD4008

• Research type

  Research Study

• Full title

  A Non-interventional Cohort Study of Esketamine-Nasal Spray in Treatment-Resistant Depression in Europe

• IRAS ID

  292395

• Contact name

  Allan Young

• Contact email

  kch-tr.research@nhs.net

• Sponsor organisation

  Janssen-Cilag Ltd.

• Duration of Study in the UK

  1 years, 9 months, 1 days

• Research summary

  Although the use of current antidepressive treatment options are, in most cases, well established in clinical practice and well described in international MDD treatment guidelines, there is no specific or unanimous guidance on TRD regarding the best approach to continuation/maintenance phases of treatment with current antidepressive treatments.This non-interventional study will collect important data from routine clinical practice, in a broader population than previously studied in selected European countries, with the aim of understanding:
  - the clinical, social, and economic outcomes of esketamine-NS treatment in patients with TRD,
  - treatment dosing, frequency and duration for esketamine-NS in the clinical setting, the impact on safety, the clinical, social, and economic outcomes up to 6 months following the discontinuation of esketamine-NS. The data from this cohort study will further substantiate the understanding of esketamine-NS use in the treatment of TRD in participating European countries with the aim of improving guidance and informing the development of better treatment strategies for this medically important condition.

• REC name

  London - South East Research Ethics Committee

• REC reference

  21/LO/0087

• Date of REC Opinion

  4 Feb 2021

• REC opinion

  Unfavourable Opinion